Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	[1]
Income Statement [Abstract]
Revenue	$ 244,293	$ 148,211
Operating expenses:
Cost of revenue	40,032	31,391
Selling, general and administrative	33,200	23,471
Research and development	3,695	2,160
Total operating expenses	76,927	57,022
Income from operations	167,366	91,189
Other income (expense):
Interest expense	(2,664)	(7,904)
Loss on extinguishment of debt	(208)	0	[2]
Change in payable to related parties pursuant to a Tax Receivable Agreement	2,340	5,886
Other income	7	3
Income before income taxes	166,841	89,174
Income tax expense	19,981	13,709
Net income	146,860	75,465	[3]
Net income attributable to non-controlling interests	79,998	52,363
Net income attributable to Maravai LifeSciences Holdings, Inc.	$ 66,862	$ 23,102
Net income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:
Basic (in usd per share)	$ 0.51	$ 0.24
Diluted (in usd per share)	$ 0.50	$ 0.24
Weighted average number of Class A common shares outstanding:
Basic (in shares)	131,489	96,647
Diluted (in shares)	255,287	96,673

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

[2] As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

[3] As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.